NEWTOWN, Pa.--(BUSINESS WIRE)--Helius Medical Technologies (CSE: HSM) (“HMT”, “Helius” or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma, is pleased to announce the appointment of Dr. Sackier as Chief Medical Officer (CMO). Dr. Sackier brings to his role as Chief Medical Officer more than 30 years of industry experience as an innovator and pioneer of new technologies. He is widely recognized as one of the leaders of the laparoscopic surgery revolution.
"I am honored to be part of such an important area of neurological science to help bring promising new technologies for patients seeking symptom relief. It represents one of the largest areas of unmet medical needs and I am proud to be a part of this growing company," said Jonathan Sackier, CMO of Helius.
“Jonathan Sackier is a highly regarded national health care expert who not only understands the challenges of health care today, but has experience bringing new technologies to market. As Helius plans to dramatically increase its clinical activity, we are very pleased to have Dr. Sackier not only as the Chair of our Scientific Advisory Board but also in the key position of Chief Medical Officer,” said Philippe Deschamps, CEO of Helius.
A trained surgeon, Dr. Sackier has helped build several companies including medical technology, research and product-design and medical contract sales organizations. He has also collaborated extensively with pharmaceutical and medical device technology partners including Bristol Myers, Pfizer, Karl Storz, Applied Medical, Stryker, Siemens, Bayer and Novartis.
Prior to joining Helius, Dr. Sackier served as Chairman of Adenosine Therapeutics, which became part of Clinical Data and then Forest Laboratories. He worked to develop and market the AESOP robot with Computer Motion, which successfully completed an IPO. He also founded Genethics, which patented and licensed amniotic stem cell technology.
As a Professor at George Washington University in Washington, DC, Dr. Sackier founded and funded the Washington Institute of Surgical Endoscopy, a center for education, research, innovation and technology transfer. He is currently a pro bono Visiting Professor of Surgery at the Nuffield Department of Surgical Sciences at Oxford University.
Dr. Sackier sits on the board of directors of Kypha, Clinvue, and Hemoshear. He is Chairman of the Board of The Load Zero Foundation and a Trustee of First Star and previously chaired The Larry King Cardiac Foundation Board of Governors. He has also served as a board member of The American College of Surgeons Foundation, The Surgical Fellowship Foundation and Rex Bionics. He is the winner of London’s 2014 AIM Award for outstanding achievement for most successful growth market.
A keen pilot, Dr. Sackier advises the Aircraft Owners & Pilots Association (AOPA) on medical issues germane to pilots and authors the “Fly Well” column in AOPA Pilot magazine.
About Helius Medical Technologies (HMT)
Helius Medical Technologies is a medical technology holding company focused on neurological wellness. HMT’s mission is to develop, license and acquire non-invasive treatments designed to help patients affected by neurological symptoms caused by disease or trauma. HMT intends to file for U.S. Food and Drug Administration clearance for the PoNSTM device. For more information, please visit www.heliusmedical.com.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.
Safe Harbor Statement
All statements in this news release, other than statements of historical facts, are forward-looking statements. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include risks detailed from time to time in the filings made by the Company with securities regulators.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update the forward-looking statements except as required by applicable law.
